Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Impax Buyouts Add Plant, Portfolio And Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

By acquiring three interrelated, privately held companies, Impax adds several branded and generic products, a substantial generic pipeline and an FDA-licensed manufacturing site in New Jersey.

You may also be interested in...



All-Star CEOs Discuss Pricing, But Come Up Short On Solutions

"Unless we make changes in the system people won’t be able to afford" drugs coming out of our pipelines, Merck’s Frazier says; Pfizer’s Read contends competition is best way to curtail prices.

UCB Ups Funding For M&A, Debt Repayment By Selling Kremers Urban

Belgium’s mid-sized pharma sells its U.S. generics business to two private equity companies, improving its flexibility to acquire new assets and businesses, and allowing it to pay down debt.

Impax CEO’s Strategy: Aggressive BD, Restructure R&D And Cut Costs

Since Impax Laboratories’ CEO Wilkinson took the helm in April, the company has completed several significant deals and most recently restructured R&D to deliver savings, but a successful turnaround will require resolving outstanding manufacturing issues.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS076612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel